Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 2084-2090

  Ewesuedo, R B ^a   Iyer, L ^a   Das, S ^a   Koenig, A ^a   Mani, S ^a   Vogelzang, N J ^a   Schilsky, R L ^a   Brenckman, W ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; GLUCURONOSYLTRANSFERASE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; GENOTYPE; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0035300677     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.2084     Document Type: Article

References (19)

1. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II
2. DNA topoisomerases: Essential enzymes and lethal targets
3. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells
4. Simultaneous determination of a novel anticancer drug, TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction
5. Glucuronidation of TAS-103: A novel anticancer agent
6. Endogenous substrates for UDP-glucuronosyltransferases
7. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
8. The uridine diphosphate glucuronosyltransferase multigene family: Function and regulation
9. Biotransformation of xenobiotics
10. Genetic background of constitutional unconjugated hyperbilirubinemia
11. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I
12. A phase I dose escalation, safety, tolerability, and pharmacokinetic study of TAS-103 in patients with refractory solid tumors
13. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome
14. Study on pharmacokinetics of new anticancer agent TAS-103
15. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
16. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11)
17. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
18. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: A common missense mutation among Japanese, Koreans and Chinese
19. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase IA1 gene in healthy Taiwanese